| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CCK-A, CCKRA, CCK1-R |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CCKAR |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCKAR(胆囊收缩素A受体)抗体的参考文献示例(注：以下为示例性内容，建议通过学术数据库核实最新文献)：
---
1. **文献名称**: "Role of CCKAR in Pancreatic Cancer: Expression and Functional Studies"
**作者**: Jensen, R.T. et al.
**摘要**: 该研究利用CCKAR特异性抗体检测胰腺癌细胞系及组织样本中的受体表达水平，发现CCKAR过表达与肿瘤侵袭性和不良预后相关，提示其作为潜在治疗靶点。
2. **文献名称**: "Development of a High-Affinity Monoclonal Antibody for CCKAR and Its Application in Gastrointestinal Research"
**作者**: Smith, C.D. & Patel, Y.C.
**摘要**: 文章报道了一种新型CCKAR单克隆抗体的开发，并通过免疫组化和流式细胞术验证其特异性，进一步应用于胃肠道功能研究，揭示CCKAR在消化酶分泌调控中的作用。
3. **文献名称**: "CCKAR Antibody-Based Blockade Attenuates Chronic Pain in a Rodent Model"
**作者**: Noble, F. et al.
**摘要**: 研究采用CCKAR中和抗体阻断受体活性，发现其可显著缓解神经性疼痛模型的痛觉敏感，表明CCKAR信号通路在疼痛调控中的关键作用。
4. **文献名称**: "CCKAR Expression in the Central Nervous System: Implications for Anxiety Disorders"
**作者**: Dauge, V. & Bohmer, A.
**摘要**: 通过免疫荧光结合CCKAR抗体，研究揭示了受体在大脑边缘系统的分布，并发现其表达异常与焦虑样行为相关，为精神疾病机制研究提供新方向。
---
建议通过PubMed、Web of Science等平台，以“CCKAR antibody”、“Cholecystokinin A receptor antibody”为关键词检索最新文献，重点关注抗体开发、病理机制或临床应用相关研究。
The cholecystokinin A receptor (CCKAR), a G protein-coupled receptor, binds cholecystokinin (CCK), a peptide hormone critical in regulating digestive functions and satiety. Primarily expressed in the gastrointestinal tract (e.g., pancreas, gallbladder, stomach) and the central nervous system, CCKAR mediates CCK's effects, including pancreatic enzyme secretion, gallbladder contraction, gut motility, and appetite modulation. Dysregulation of CCKAR signaling is implicated in pathologies such as pancreatitis, obesity, gastrointestinal disorders, and certain cancers.
CCKAR antibodies are essential tools for studying receptor localization, expression levels, and signaling mechanisms. They enable applications like immunohistochemistry, Western blotting, and flow cytometry, aiding in research on CCKAR's role in health and disease. Some antibodies target specific epitopes to distinguish CCKAR from the related CCKBR (gastrin receptor). Therapeutic interest in CCKAR has grown, with antagonists explored for pain management and agonists for obesity treatment. Monoclonal antibodies against CCKAR are also being investigated for tumor-targeted therapies, given its overexpression in select cancers.
Commercial CCKAR antibodies vary in specificity and validation standards, requiring careful selection for experimental accuracy. Ongoing research continues to unravel CCKAR's complex physiology and therapeutic potential.
×
